Edwards Lifesciences faced a setback as the US District Court for the District of Columbia approved an injunction motion issued by the US Federal Trade Commission (FTC), halting the medtech giant’s plans to acquire JenaValve. This decision means that Edwards will no longer proceed with the acquisition of JenaValve, a company known for its transcatheter aortic valve replacement system for aortic regurgitation (TAVR-AR). Despite disagreeing with the court’s ruling, Edwards believed that the acquisition would have benefited a large and underserved patient population.
As a result of this development, Edwards has revised its full-year 2026 earnings guidance to a range of $2.90-$3.05 per share, up from $2.80-$2.95 previously. The company stated that it will now focus on advancing the SOJOURN transcatheter AR valve and enrolling patients in the JOURNEY pivotal trial (NCT06455787) evaluating the J-Valve TAVR AR system.
The acquisition of J-Valve from JC Medical in August 2024 was part of Edwards’ strategy to strengthen its structural heart portfolio. JenaValve’s lead product, the Trilogy Heart Valve, is pending FDA approval after being in clinical trials under an investigational device exemption (IDE) granted in 2021.
The FTC filed a lawsuit against Edwards in August 2025 to block the acquisition of JenaValve, citing concerns about competition and innovation in the TAVR-AR space. With JC Medical now a subsidiary of Edwards, the FTC argued that the acquisition of JenaValve would eliminate competition and stifle innovation in the market.
Following the court’s decision, Edwards’ share price on the NYSE fell by 1.32% to $84.01 in pre-market trading on 12 January. The company, with a market cap of $50 billion, released its statement after markets closed on 9 January.
According to GlobalData analysis, the overall TAVR market is projected to double its valuation to $12.8 billion by 2034, with a compound annual growth rate (CAGR) of 7.2%. The addition of AR as a new indication in the treatment modality could potentially accelerate the market’s CAGR into double digits.
In conclusion, Edwards’ failed attempt to acquire JenaValve is a significant development in the medtech industry. The company now faces the challenge of navigating the competitive landscape in the TAVR-AR space while continuing to innovate and meet the needs of patients.
